Astellas And Effector Cell Institute To Jointly Develop Autoimmune Drug
This article was originally published in PharmAsia News
Astellas Pharma has signed a licensing deal with Tokyo-based Effector Cell Institute to develop a new drug based on the novel target protein FROUNT in the area of autoimmune disorders, such as transplant rejection and rheumatoid arthritis. Under the license, Effector will receive an up-front payment and research fees, as well as development milestones related to the compound. (Click for more-Japanese language
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.